Stealth Health buys Canada's Kramer to link telemedicine with drug compounding
What's the deal? Stealth Health, a North American telemedicine platform focused on longevity and personalised healthcare, has acquired KramerDealroom has a profile for this one. Try Dealroom →, a Canadian company that connects retail pharmacies with specialised compounding partners. The deal, announced in October 2026, is complete. Terms were not disclosed.
What's the endgame? Stealth Health wants to build what it calls a fully integrated healthcare ecosystem, linking virtual consultations, prescribing, compounding, and delivery. Kramer adds a nationwide compounding network to that chain.
Why now? Patients prescribed compounded medications in Canada often struggle to find a pharmacy equipped to prepare them. Kramer bridges that gap by routing prescriptions to compounding partners while letting referring pharmacies keep their patient relationships.
Stealth Health plans to fold Kramer's capabilities into its digital platform and enterprise white-label network, which serves clinics and wellness brands. Its services span hormone optimisation, weight management, sexual wellness, and preventive health.
In their words: "Personalized medicine only works if patients can actually get the medication their clinician prescribed, and this acquisition helps make that seamless," said Matthew Mazzuca, chief executive officer of Stealth Health.
What could go wrong? Health Canada has warned that compounding must stay patient-specific and cannot be used to bypass drug approval. The regulator has taken enforcement action over unauthorised GLP-1 products, meaning any expansion of compounded access operates within tight limits.
The signal: The deal fits a broader push to consolidate and scale pharmacy access through digital platforms. But with price, scale, and terms undisclosed, its full significance is hard to gauge beyond Stealth Health adding a compounding operation to its stack.
Read more: newswire.ca
Image credit: Usekramer
